Larvol Delta - Alopexx-Oncology-announces-licensing-agreement-with-Beijing-Shenogen-Pharma-Group-for-development-and-commercialization-of-novel-immunocytokine-for-the-treatment-of-Bcell-lymphomas-in-ChinaAsia

DI Leu16 IL-2 - Provenance, Alopexx

https://www.prnewswire.com/news-releases/alopexx-oncology-announces-licensing-agreement-with-beijing-shenogen-pharma-group-for-development-and-commercialization-of-novel-immunocytokine-for-the-treatment-of-b-cell-lymphomas-in-chinaasia-301016101.html

Mar 4, 2020

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next